HSPA12B is a newly discovered and endothelial-cell-specifically expressed heat shock protein. We have reported recently that overexpression of HSPA12B increased endothelial nitric oxide synthase (eNOS) expression in mouse cardiac tissues during endotoxemia. Endothelial NOS has been shown to protect heart from ischaemic injury. We hypothesized that overexpression of HSPA12B will attenuate cardiac dysfunction and remodelling after myocardial infarction (MI) through an eNOS-dependant mechanism.
Introduction
Cardiac dysfunction after myocardial infarction (MI) is one of the leading causes of death worldwide. Although recent medical advances have improved survival in patients with MI, therapies directed towards the deleterious consequences of MI damage remain limited.
1,2 Therefore, it is important to develop alternative cardioprotective strategies. Heat-shock protein A12B (HSPA12B) was discovered in human atherosclerotic lesions in 2003. 3 Subsequent studies by us and others have revealed that HSPA12B is specifically expressed in endothelial cells of blood vessels. 4 -6 These studies have also shown that HSPA12B is indispensable for the tube formation of endothelial cells and for the vessel development of zebrafish. 4 -6 However, it is unknown whether and how HSPA12B regulates angiogenic process in mammalians.
A potent cardioprotection of HSPA12B against endotoxin challenge was shown in our recent study, which demonstrates that overexpression of HSPA12B attenuates cardiac dysfunction during endotoxemia. 6 Interestingly, we observed that the HSPA12B-induced cardioprotection † These authors contributed equally to this study.
against endotoxin challenge involves the up-regulation of endothelial nitric oxide synthase (eNOS). 6 Moreover, we have shown very recently that overexpression of HSPA12B protects brain against acute cerebral ischaemia/reperfusion injury. 7 However, the roles of HSPA12B in the pathogenesis of cardiac dysfunction and remodelling after MI have not been investigated. Endothelial NOS has been well documented to play a critical role in attenuating cardiac dysfunction and deleterious remodelling after MI. 8 -15 As examples, increased eNOS expression protects against cardiac remodelling and dysfunction after MI. 9, 14 Conversely, decrease or lack of eNOS expression negates the exercise-induced attenuation of cardiac dysfunction after MI. 15 The mechanism of eNOS-induced cardioprotection after MI involves prevention of cardiomyocyte apoptosis and promotion of myocardial angiogenesis. 9, 10, 14 Importantly, eNOS has been proposed as one of the effective targets of gene therapy for cardiac ischaemic diseases. 8 We have shown an increased expression of eNOS by HSPA12B in mouse cardiac tissues during endotoxemia. 6 We hypothesized that overexpression of HSPA12B will attenuate cardiac injury after MI through up-regulation of eNOS. In the present study, we demonstrated for the first time that overexpression of HSPA12B significantly improves cardiac dysfunction and reduces remodelling after MI. These actions of HSPA12B were mediated, at least in part, by prevention of cardiomyocyte apoptosis and promotion of angiogenesis through an eNOSdependent mechanism. Our results suggest that HSPA12B could be a novel target for the management and treatment of patients with cardiac dysfunction and remodelling after MI.
Methods

Antibodies and reagents
N v -Nitro-L-arginine methyl ester hydrochloride (L-NAME), triphenyltetrazolium chloride (TTC), primary antibodies for a-smooth muscle actin (SMA), a-actinin, and a-tubulin were purchased from Sigma-Aldrich (St Louis, MO, USA). The primary antibody for HSPA12B was a kind gift from Dr Zhihua Han (East Tennessee State University, Johnson City, TN, USA). Primary antibodies for aB-crystallin (aBC), Hsp25, Hsp60, Hsp72, and Hsp90 were from Stressgen (Victoria BC, Canada), for Bcl-2 and Bax from Cell Signaling Technology (Beverly, MA, USA), for PCAM-1 from BD Pharmingen (San Jose, CA, USA), for eNOS and iNOS from BD Biosciences (Bedford, MA, USA), and for VEGF and angiopointin-1 (Ang-1) from Abcam (Cambridge, UK). The TUNEL assay kit was from Promega (Madison, WI, USA). The LightShift Chemiluminescent EMSA kit and the supersignal west pico chemiluminescent substrate were obtained from Pierce (Rockford, IL, USA).
Mice
Transgenic mice overexpressing the human hspa12b gene (Tg) were developed as described in our previous studies. 6 Mice were bred and maintained at the Model Animal Research Center of Nanjing University and maintained in the Animal Laboratory Resource Facility at Nanjing University. All the experiments conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011) and the principles outlined in the Declaration of Helsinki 16 for use of human tissue or subjects. The animal care and experimental protocols were approved by the Nanjing University Committee on Animal Care.
All the experiments were conformed to the international guidelines on the ethical use of animals.
Myocardial infarction
MI was induced in 8-to 10-week-old Tg mice and wild-type (WT) littermates by permanent ligation of the left anterior descending (LAD) coronary artery. All procedures were carried out as recently described. 17, 18 Male mice were used in this study because estrogen-dependent signalling has been reported to play protective roles in myocardial ischaemic injury including postischaemic cardiac dysfunction. 19, 20 Mice were anaesthetized by sodium pentobarbital (50 mg/kg, intraperitoneal injection). The adequacy of anaesthesia was assayed by the disappearance of righting reflex and pedal withdrawal reflex. After anaesthesia, mice were subjected to mechanical ventilation, tnoracotomy along the left sternal border, and permanent LAD ligation. In sham-operated animals, the same procedure was performed except the LAD occlusion. For analgesia, buprenorphine (0.05 mg/kg) was administrated subcutaneously prior to surgery, and administrated every 8 h for the next 48 h. For tissue collection, mice were sacrificed by overdose anaesthesia (pentobarbital sodium 150 mg/kg intraperitoneal injection) and cervical dislocation.
L-NAME treatment
For the experiments performed at 24 h after MI, mice were administrated with L-NAME (15 mg/kg) intraperitoneally 30 min prior MI. 21 For the experiments performed at 1 week after MI, mice were given drinking water containing L-NAME (1 mg/ml, daily prepared) immediately after MI. 22 
Determination of myocardial infarct size
Infarct size was examined by TTC staining, as described previously. 23 At 24 h after LAD ligation, the hearts were removed and perfused with saline before staining with 1% Evans Blue. The hearts were then sliced and incubated in 1.5% TTC for 30 min at 378C. Ratios of risk area vs. left ventricle (LV) and infarct area vs. LV were calculated and expressed as a percentage. Ten mice were used for MI operation.
Echocardiography
Two-dimensional echocardiographic measurements were performed using the Vevo770 system equipped with a 35-MHz transducer (Visualsonics, Toronto, Canada) as our previous methods. 6 Mice were anaesthetized with inhalation of 1.5-2% isoflurane. The measurements were performed by an observer blinded to the treatment. The parameters were obtained in the M-mode tracings at the papillary muscle level and averaged using three to five cardiac cycles. The values obtained in the mice without any interventions served as basal controls. Thirty-three mice were in baseline group, 38 mice in MI group, 7 mice in sham-/ L-NAME group, and 18 mice in MI/ L-NAME group.
Fibrosis
Heart tissues at the papillary muscle level were collected for paraffinsectioning. Masson trichrome staining was used to analyse the fibrosis according to the methods described previously. 17 Nine mice were used for MI operation.
Angiogenesis in periinfarct areas
Heart tissues at the papillary muscle level were collected for cryosectioning. The angiogenesis in periinfarct areas was evaluated by capillary and arteriolar densities, which were examined by immunofluorescence staining for PCAM-1 and SMA, respectively. 6, 17 The images were taken with a fluorescent microscope (Axiovert 200, Zeiss Ltd., Germany). The number of capillaries and arteries was counted in more than five random fields in the periinfarct areas. Densities were expressed as the counts of capillaries or arterioles per field. Seven mice were in sham group, 17 mice in MI group, and 7 mice in MI/ L-NAME group.
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Cardiomyocyte apoptosis in periinfarct areas
Heart tissues at the papillary muscle level were collected for paraffinsectioning. Cardiomyocyte apoptosis was examined using the TUNEL assay according to our previously described methods. 24 Alpha-actinin was used to stain cardiomyocytes. Hoechst 33342 reagent was used to counterstain the nuclei. Cardiomyocyte apoptosis in the periinfarct areas was observed using a fluorescent microscope (Axiovert 200, Zeiss Ltd., Germany). More than four fields in the periinfarct areas on each slide were randomly examined. Three mice were in the sham group, three mice in the MI group, and four mice in the MI/L-NAME group.
Western blot
Hearts were collected at 24 h after MI. Western blots were performed on these samples as described in our previous studies. 6, 24 Briefly, cellular proteins were prepared from heart samples, separated on 10% SDS -PAGE, and transferred onto Immobilon-P membranes (Millipore). The membranes were probed with appropriate primary antibodies followed by incubation with peroxidase-conjugated secondary antibodies. The signals were detected by enhanced Pierce chemiluminescence. For loading control, the same membranes were probed with anti-a-tubulin. The signals were quantified by scanning densitometry and the results from each experimental group were expressed as relative integrated intensity compared with that of controls. Four mice in the baseline group, four mice in the sham group, four mice in the MI group, and four mice in the MI/L-NAME group.
Statistical analysis
The results are expressed as means + standard deviation (X + SD). Comparisons between the groups were performed using the one-way analysis of variance (ANOVA). Post hoc procedure (Tukey's test) for multiple range tests was performed. P , 0.05 was considered to be significant.
Results
Overexpression of HSPA12B attenuates cardiac dysfunction after MI
Cardiac function was examined by echocardiography at 1 and 4 weeks after MI. As shown in Figure 1 and Table 1 , MI significantly decreased cardiac function in WT mice, as evidenced by decreases in EF%, FS%, and SV, when compared with WT basal controls (P , 0.01). In contrast, the MI-induced decreases in EF%, FS%, and SV were significantly attenuated in Tg mice, respectively, in comparison with WT mice. No significant differences between WT and Tg groups were observed at baseline.
Overexpression of HSPA12B attenuates cardiac remodelling after MI
Cardiac remodelling, which was reflected by changes in LV diameter and wall thickness, were examined by echocardiography at 1 and 4 weeks after MI ( Figure 1 and Table 1 ). WT mice exhibited progressive LV enlargement after MI as indicated by increases in LVIDd, LVIDs, LVVd, and LVVs, respectively, compared with WT basal controls (P , 0.01). WT mice also exhibited progressive LV wall thinning after MI as evidenced by decreases in IVSd, IVSs, LVPWd, and LVPWs, respectively, compared with WT basal controls (P , 0.01). Interestingly, the MI-induced LV enlargement and wall thinning were significantly prevented in Tg mice, respectively, compared with WT mice (P , 0.01 or 0.05). Sham operation did not significantly change all the measured LV morphologic parameters in WT and Tg mice, respectively, compared with their baseline controls (see Supplementary material online, Figure  S3 and Table S1 ).
Overexpression of HSPA12B reduces fibrosis after MI
The fibrosis permeation was analysed in the hearts of WT and Tg mice at 4 weeks after MI. As shown in Figure 2 , the fibrosis area in Tg MI mice was significantly less than in WT MI mice (24.6 + 4.3 vs. 34.2 + 4.4%, P , 0.05).
Overexpression of HSPA12B reduces cardiomyocyte apoptosis in the periinfarct areas
Cardiomyocyte apoptosis is believed to be an important mechanism for the development of cardiac dysfunction and remodelling after MI.
25,26 Figure 3 shows that MI for 24 h significantly increased cardiomyocyte apoptosis in the periinfarct areas in both WT and Tg mice, respectively, compared with their sham controls (P , 0.01). However, the MI-induced cardiomyocyte apoptosis was significantly reduced by 24.9% in Tg mice compared with WT mice (P , 0.01). Promoted angiogenesis has been shown to facilitate myocardial recovery from ischaemic injury. 8, 27, 28 As shown in Figure 4A and B, MI for 4 weeks significantly increased capillary and arteriolar density in the periinfarct areas in both WT and Tg mice, respectively, compared with their sham controls (P , 0.01 or 0.05). Interestingly, Tg MI mice exhibited significantly higher capillary density by 23.4% and arteriolar density by 75.7%, respectively, in comparison with WT MI mice (P , 0.01).
There was no significant difference in the capillary and arteriolar density between WT sham and Tg sham groups.
Overexpression of HSPA12B increases
Bcl-2 level and Bcl-2/Bax ratio in the cardiac tissues after MI Bcl-2 and Bax are well-known regulators of apoptosis during ischaemia. 7, 25 Bcl-2 is an important anti-apoptotic protein, while Bax is a pro-apoptotic effector. Figure 5A shows that MI significantly increased Bcl-2 levels in both WT and Tg mice, respectively, compared with their sham controls (P , 0.01 or 0.05). However, the Bcl-2 level was significantly higher by 27.5% in Tg MI mice than in the WT MI mice (P , 0.05). Furthermore, the Bcl-2/Bax ratio was significantly higher in Tg MI mice than in both Tg sham and WT MI mice (P , 0.05). 
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No significant difference of Bax levels was detected between WT mice and Tg mice after MI.
Overexpression of HSPA12B increases the expression of VEGF and Ang-1 in the cardiac tissues after MI
VEGF and Ang-1 are two critical pro-angiogenic factors. 8, 11, 29 Figure 5B
shows that MI significantly increased the levels of VEGF and Ang-1 in both Tg and WT groups, respectively, compared with their sham controls (P , 0.01 or 0.05). However, the MI-induced increases in VEGF and Ang-1 levels were markedly enhanced in Tg mice by 52.6% and 39.0%, respectively, when compared with WT mice (P , 0.01 or 0.05).
Overexpression of HSPA12B increases eNOS expression in the cardiac tissues after MI
Both eNOS and iNOS are considered to be important regulators for myocardial angiogenesis and cardiomyocyte apoptosis after MI. 14, 30 Particularly, eNOS has been demonstrated to positively regulate the expression of other pro-angiogenic factors, such as VEGF. 11 As shown in Figure 5C , MI significantly increased eNOS levels by 195.4% in Tg mice Figure 3 Overexpression of HSPA12B reduced cardiomyocyte apoptosis in the periinfarct areas. Cardiac tissues at papillary muscle level were harvested at 24 h after MI. Paraffin-sections were prepared. A TUNEL assay was performed to detect cardiomyocyte apoptosis. Alpha-actinin was used to stain cardiomyocytes. Hoechst 33342 reagent was used to counterstain the nuclei. TUNEL-positive cardiomyocytes in the periinfarct areas were observed using a fluorescent microscope at a magnification of ×400. n ¼ 3/group, *P , 0.01. Figure 4 Overexpression of HSPA12B promoted angiogenesis in the periinfarct areas. Cardiac tissues at papillary muscle level were harvested at 4 weeks after MI. Cryosections were prepared for immunofluorescence staining for capillaries (PCAM-1, A) and arterioles (SMA, B). The number of capillaries and arterioles in periinfarct areas was counted using a fluorescent microscope at magnifications of ×400 and ×100, respectively. Higher magnifications of boxed areas were illustrated in the down panel (A). The densities were expressed as the counts of capillaries or arterioles per field. n ¼ 3 -4/sham group, n ¼ 5/MI group. *P , 0.01, # P , 0.05.
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and by 58.8% in WT mice, respectively, compared with their sham controls (P , 0.01 or 0.05). Thus, the MI-induced up-regulation of eNOS was markedly enhanced in Tg mice by 232.6% compared with WT mice (P , 0.05). MI did not significantly change iNOS levels in both WT and Tg mice. Consistently, as shown in see Supplementary material online, Figure S6 , MI significantly increased myocardial NOS activity by 153.8% in WT and 278.9% in Tg mice, respectively, compared with their sham controls (P , 0.01). The NOS activity was significantly higher by 72.7% in Tg hearts than in WT hearts after MI (P , 0.05).
Treatment with L-NAME abrogates the protective effects of HSPA12B on cardiac dysfunction and remodelling after MI
To determine the roles of up-regulated eNOS in HSP12B-induced cardioprotection, we treated mice with L-NAME, a specific inhibitor for NOS. The cardiac function and LV morphometric features were analysed at 1 week after MI by echocardiography. As shown in Figure 6A and Table 2 , treatment with L-NAME prevented the HSPA12B-induced protection in cardiac dysfunction after MI, as evidenced by significant decreases in EF% and FS%, respectively, compared with Tg MI mice that did not receive L-NAME treatment (P , 0.01). Importantly, no significant difference of EF% and FS% was observed between Tg MI and WT MI mice following L-NAME treatment. Figure 6A and Table 2 also show that L-NAME prevented the HSPA12B-induced protection against LV enlargement after MI, as evidenced by significant increases in LVIDd, LVIDs, LVVd, and LVVs, respectively, compared with Tg MI mice that did not receive L-NAME administration (P , 0.01). The protection of HSPA12B in LV wall thinning after MI was also prevented by L-NAME, as indicated by significantly decreases in IVSd, IVSs, and LVPWd, respectively, compared with Tg MI mice that did not receive L-NAME administration (P , 0.01 or 0.05). Figure 5 Overexpression of HSPA12B increased the expression levels of Bcl-2, VEGF, Ang-1, and eNOS in the cardiac tissues following MI. The cardiac tissues were harvested at 24 h after MI. The cellular proteins were prepared for immunoblot analysis with specific antibodies for Bcl-2 and Bax (A), for VEGF and Ang-1 (B), and for eNOS and iNOS (C). The same membrane was blotted with a-Tubulin to serve as a loading control. n ¼ 4/group. *P , 0.01, # P , 0.05. Figure 6 L-NAME treatment abrogated HSPA12B-induced cardiac protection after MI. (A) Cardiac dysfunction and remodelling. Mice were administrated with L-NAME in drinking water immediately after MI surgery. Cardiac function and remodelling were evaluated by echocardiography at 1 week after MI. The representative M-mode images of echocardiography are shown. n ¼ 9-10/group. (B) Cardiomyocyte apoptosis. Mice were administrated with L-NAME intraperitoneally 30 min before MI surgery. Cardiac tissues at papillary muscle level were collected at 24 h after MI and prepared for paraffin-sectioning. Cardiomyocyte apoptosis in the periinfarct areas was evaluated by TUNEL assay. n ¼ 3-4/group. *P , 0.01, # P , 0.05. (C) Capillary formation. Mice were administrated with L-NAME in drinking water immediately after MI surgery. Cardiac tissues at papillary muscle level were collected at 1 week after MI and prepared for cryosections. Higher magnifications of boxed areas were illustrated in the down panel. Capillary density in the periinfarct areas was analysed by PCAM-1 staining. n ¼ 3-4/ group, *P , 0.01. (D) VEGF and Ang-1 expression. Mice were administrated with L-NAME intraperitoneally 30 min before MI surgery. Cardiac tissues were collected at 24 h after MI. The cellular proteins were prepared for immunoblot analysis with specific antibodies. n ¼ 4/group. *P , 0.01.
Significantly, no significant difference of LVIDd, LVIDs, LVVd, LVVs, IVSd, IVSs, and LVPWd was observed between Tg MI and WT MI mice following L-NAME treatment.
L-NAME administration did not significantly change cardiac function and LV morphometric features in sham mice when compared with basal controls (see Supplementary material online, Figure S8 and Table S2 ).
3.10. L-NAME abolishes the protection of HSPA12B from cardiomyocyte apoptosis in the periinfarct areas L-NAME treatment significantly increased cardiomyocyte apoptosis in the periinfarct areas by 19.1% in WT MI mice and 52.5% and Tg MI mice, respectively, compared with WT MI and Tg MI mice that did not receive L-NAME treatment (P , 0.05). Interestingly, no significant difference of cardiomyocyte apoptosis was observed between Tg MI and WT MI groups following L-NAME treatment (45.9 + 7.3 vs. 47.7 + 4.0%, P . 0.05) ( Figure 6B ). Moreover, no significant difference of fibrosis areas was observed between MI-WT and MI-Tg mice in the presence of L-NAME (see Supplementary material online, Figure S9 ).
3.11 L-NAME removes the HSPA12B-induced capillary formation in the periinfarct areas
The effect of L-NAME on the HSPA12B-induced capillary formation was examined in the periinfarct areas at 1 week after MI. In L-NAME nontreated groups, Tg MI mice showed significant higher capillary density compared with WT MI mice (P , 0.01). However, treatment with L-NAME significantly decreased the capillary density in Tg MI mice compared with Tg MI mice that did not receive L-NAME treatment (P , 0.01). More importantly, no significant difference of capillary density was observed between Tg MI and WT MI groups following L-NAME treatment (154.5 + 7.9 counts/field vs.150.6 + 6.9 counts/ field, P . 0.05) ( Figure 6C ).
3.12. The HSPA12B-induced up-regulation of VEGF in ischaemic heart is abolished by L-NAME
As shown in Figure 6D , L-NAME significantly decreased VEGF level by 46.1% in Tg MI mice compared with Tg MI mice that did not receive L-NAME treatment (P , 0.01). Moreover, no significant difference of VEGF levels was detected between Tg MI and WT MI groups following L-NAME treatment. L-NAME did not significantly change Ang-1 levels in both Tg MI and WT MI mice, respectively, compared with Tg MI and WT MI mice that did not receive L-NAME administration.
Discussion
The significant findings in the present study were that transgenic mice with overexpression of HSPA12B exhibit significant improvements of cardiac dysfunction and remodelling after MI. The results also suggest that the cardioprotection by HSPA12B was mediated, at least in part, by prevention of cardiomyocyte apoptosis and promotion of myocardial angiogenesis via an eNOS-dependent mechanism. Heat-shock proteins (Hsps) belong to a superfamily. Several Hsps, such as aB-crystallin (aBC), Hsp20, Hsp25, and Hsp72, have been reported to increase myocardial tolerance to ischaemic challenge. 31, 32 In the present study, we observed that HSPA12B Tg mice showed a significant attenuation of cardiac dysfunction and remodelling after MI. Transgene with hspa12b only increased the expression of HSPA12B, whereas it did not change the expression of other Hsps including aBC, Hsp25, Hsp60, Hsp72, and Hsp90 (see Supplementary material online, Figure S1 ), suggesting that the observed cardioprotection in HSPA12B Tg mice was afforded by HSPA12B.
An abrupt increase in cardiomyocyte apoptosis was observed in ischaemic hearts of both patient and animals. 33, 34 Apoptosis has been proposed as an important mechanism for the elimination of cardiomyocytes after MI. 33, 35 Moreover, limitation of cardiomyocyte apoptosis has shown potential protection against post-MI cardiac dysfunction and remodelling. 25 , 26 Indeed, we observed that the MI-induced cardiomyocyte apoptosis was significantly prevented in HSPA12B Tg mice, which was positively related to the attenuation of cardiac dysfunction and remodelling. We also observed that HSPA12B Tg mice showed increased Bcl-2 level and Bcl-2/Bax ratio following ischaemic stress. These results indicate that suppression of cardiomyocyte apoptosis could contribute to the HSPA12B-induced cardioprotection after MI. Angiogenesis is an adaptive response to hypoxia and ischaemia. Increased angiogenesis has been documented to facilitate cardiac recovery from ischaemic injury. 2, 36, 37 However, the angiogenesis triggered by ischaemia is insufficient to avoid further structural and functional impairment of the ischaemic heart. 38 Thus, promoting myocardial angiogenesis is a major goal for the treatment of patients with MI. 27, 28 We observed significant higher densities of capillaries and arterioles in the periinfarct areas in Tg hearts than that in WT hearts, suggesting that overexpression of HSPA12B promotes myocardial angiogenesis after MI. In supporting our observations, previous studies have demonstrated that HSPA12B is required for tube formation of HUVECs. 3, 4 Moreover, HSPA12B orthologue has been shown to be indispensable for vessel development in zebrafish. 5 Collectively, our results suggest that overexpression of HSPA12B promoted angiogenesis in ischaemic hearts, which in turn attenuated cardiac dysfunction and remodelling after MI. Our findings also provide the first evidence for HSPA12B in the regulation of angiogenesis under pathological conditions. Endothelial NOS has shown multiple protective functions in the heart especially in cardiac ischaemic diseases. 8, 9 In MI models, eNOS gene therapy leads to decrease in infarct size and improvement in contractility. 8, 9 These actions of eNOS could be partly explained by its prevention of cardiomyocyte apoptosis and promotion of myocardial angiogenesis. As examples, up-regulation of eNOS protects heart against ischaemic injury through inhibition of cardiomyocyte apoptosis, 14 while deficiency of eNOS increases cardiomyocyte apoptosis during heart development. 13 Moreover, overexpression of eNOS has been shown to increase post-MI capillary density, whereas the angiogenic response to ischaemia is impaired in eNOS-deficient mice. 8,10 -12 Thus, eNOS serves as a negative regulator for apoptosis and positive regulator for angiogenesis after ischaemia. Indeed, we observed that MI-induced eNOS up-regulation was enhanced in Tg hearts. No significant change of iNOS was observed between sham and MI groups in both Tg and WT mice. To determine the roles of up-regulated eNOS in HSPA12B-induced cardioprotection, we treated mice with NOS inhibitor L-NAME. The results revealed that L-NAME treatment abolished the HSPA12B-induced prevention of cardiomyocyte apoptosis and promotion of capillary formation after MI. Most importantly, L-NAME treatment abrogated the HSPA12B-induced protection against post-MI cardiac dysfunction and remodelling. Furthermore, a significant LV dilation in MI-WT and MI-Tg mice in the presence of L-NAME, respectively, compared with MI-WT and MI-Tg mice that did not receive L-NAME treatment. Consistently, treatment with L-NAME significantly increased cardiomyocyte apoptosis and decreased angiogenesis in both WT and Tg mice following MI, respectively, compared with MI-WT and MI-Tg mice that did not receive L-NAME treatment. These data suggest that the increased cardiomyocyte apoptosis and decreased angiogenesis may contribute to the L-NAME -induced LV dilation in both WT and Tg mice following MI.
In conclusion, our results suggest that overexpression of HSPA12B exerted a significant cardioprotection on cardiac dysfunction and remodelling after MI. The cardioprotective action of HSPA12B was mediated, at least in part, by prevention of cardiomyocyte apoptosis and promotion of myocardial angiogenesis through an eNOSdependent mechanism.
